AI English summary of an SEC filing — figures as filed
Medtronic MDTMedtronic said Cardiovascular net sales for fiscal 2025 were $12.5 billion, an increase of 5% compared to the prior fiscal year, and Neuroscience net sales were $9.8 billion, an increase of 5%.
Key points
AI summaryMedtronic said Cardiovascular net sales for fiscal 2025 were $12.5 billion, an increase of 5% compared to the prior fiscal year, and Neuroscience net sales were $9.8 billion, an increase of 5%.
Medtronic said the increase in net sales for fiscal year 2025 was driven by growth in most businesses, including Cardiac Ablation Solutions and TAVR, with declines in Stapling and a $90 million incremental Italian payback accrual resulting from the Constitutional Court of Italy ruling on July 22, 2024 partially offsetting the increase.
Medtronic estimated the net tariff impact for fiscal 2026 to be $200 million to $350 million based on current imposed or proposed tariff rates as of May 21, 2025, with the majority recognized in the consolidated statements of income in the second half of the fiscal year.
The company announced in May 2025 its intent to separate the Diabetes business, with the intention to create a new independent, publicly traded company, and said the separation is expected to be completed within 18 months of the initial announcement.
Key figures
Fiscal year ended April 25, 2025
- Revenue
- $33.5B
- Operating income
- $6.0B
- Net income
- $4.7B
- EPS
- $3.61
- Operating cash flow
- $7.0B
From the XBRL financial data filed with the SEC · not processed by AI.
Summary
AI-writtenAnalysis scope · Management's discussion (MD&A)We analyzed excerpts of the Management's Discussion and Analysis (MD&A) section (with omissions). Other sections of the report, such as the notes to the financial statements and risk factors, were not reviewed.
Annual segment net sales growth
Medtronic said Cardiovascular net sales for fiscal 2025 were $12.5 billion, an increase of 5% compared to the prior fiscal year, and Neuroscience net sales were $9.8 billion, an increase of 5%.
Source · Based on the MD&A text of the filing
Net sales growth drivers and Italian payback accrual
Medtronic said the increase in net sales for fiscal year 2025 was driven by growth in most businesses, including Cardiac Ablation Solutions and TAVR, with declines in Stapling and a $90 million incremental Italian payback accrual resulting from the Constitutional Court of Italy ruling on July 22, 2024 partially offsetting the increase.
Source · Based on the MD&A text of the filing
Estimated tariff impact for fiscal 2026
Medtronic estimated the net tariff impact for fiscal 2026 to be $200 million to $350 million based on current imposed or proposed tariff rates as of May 21, 2025, with the majority recognized in the consolidated statements of income in the second half of the fiscal year.
Source · Based on the MD&A text of the filing
Announcement of intent to separate Diabetes business
The company announced in May 2025 its intent to separate the Diabetes business, with the intention to create a new independent, publicly traded company, and said the separation is expected to be completed within 18 months of the initial announcement.
Source · Based on the MD&A text of the filing
AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.
Original filing
The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.
Loading the filing text…